Howmet Aerospace Inc vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Howmet Aerospace Inc trades at $225.24 (market cap $88.76B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B). The key difference: Howmet Aerospace Inc is far larger — about 14.7× Iovance Biotherapeutics Inc. Common Stock's market cap, and Howmet Aerospace Inc pays a 0.25% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| HWM | IOVA | |
|---|---|---|
Market Cap | $88.76B | $6.04B |
Volume | 2,648,516 | 14,805,993 |
Sector | Industrials | Health |
52-Week High | $292.65 | $14.82 |
52-Week Low | $184.09 | $1.81 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $92.86B | $5.97B |
Dividend Yield | 0.25% | — |
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $225.24, up 1.14% with strong fundamental performance including three consecutive quarterly earnings beats. The stock shows bearish technical signals despite robust profitability metrics with 20.52% net income margin and 34.89% ROE. Recent news highlights defense aerospace strength and upcoming Q3 2026 earnings announcement on October 29, 2026.
Analyst consensus remains strongly bullish with 84% buy ratings and $328.10 price target representing 46% upside potential. Key risks include technical weakness, valuation multiples above industry averages, and dependence on aerospace sector recovery. The combination of strong fundamentals and analyst optimism suggests potential for recovery from current technical pressure.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →